Moolec Science SA

Moolec Science SA(MLEC)股票分析

$0.850

0.000 (0.00%)收盘时

Loading chart…
最高
0.850
开盘
0.850
成交量加权均价
—
成交量
0.00
市值
40.57M
最低
0.850
成交额
0.00
企业价值/息税折旧摊销前利润(TTM)
0.00

Moolec Science SA is a science-based food ingredient company. The Company operates an integrated platform encompassing research & development (R&D), manufacturing, and regulatory capabilities that span from molecular design to validation in both fermenter and field environments. It operates across the United States, Europe, and South America. The Company advances its molecular farming programs in crops such as soy and safflower to produce proteins and lipids with animal-like functionality and plant-based cost structures. It is developing a precision fermentation facility in Finland, under the SynBio Powerlabs brand, which will be dedicated to producing target proteins, enzymes, and other biomolecules using optimized microbial and cellular systems. Its product portfolio includes GLASO, PIGGY SOOY, VALORASOY, and MYCOFOOD. Its GLASO, a safflower-derived oil rich in functional lipids, is being used in formulations for small-animal feed.

AI 分析 of Moolec Science SA (MLEC)

卖出

Moolec Science SA (MLEC) is not a good buy right now. The current price is $0.85, which is significantly down 79.47% year-to-date and 91.63% over the past year. The RSI is at an extremely low 10.62, indicating the stock is oversold, but this does not guarantee a rebound. The gross margin is negative at -17.81%, reflecting ongoing financial struggles. Additionally, the company's debt to equity ratio is alarmingly high at 789.74%, posing a serious risk to financial stability. While there was a recent surge in stock price due to a reverse stock split and increased shareholder interest, the overall performance and financial health suggest caution. The main risk is the high debt level, which could hinder recovery efforts and investor confidence.

估值指标

Moolec Science SA(MLEC)当前预期市盈率为 0.00,5 年平均预期市盈率为 -6.20。

预期市盈率

高估
5 年均值 P/E
-6.20
当前P/E
0.00
高估
-1.34
低估
-11.06

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-6.44
当前EV/EBITDA
0.00
高估
0.90
低估
-13.78

预期市销率

合理
5 年均值 P/S
9.15
当前P/S
0.07
高估
25.82
低估
-7.52

Alphio AI 对 MLEC 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%MLEC

$29.13

情景价格

基

基准

基准 · 50%MLEC

$22.46

情景价格

悲

悲观

悲观 · 25%MLEC

$17.06

情景价格

事件时间线

2026-07-15 (ET)

10:30:00

Moolec Science SA Trading Halted Due to Volatility Trading Pause

2026-05-14 (ET)

09:20:00

Moolec Science Completes 2026 GLASO Commercial Planting Campaign

2026-04-29 (ET)

09:10:00

Moolec Science Completes First Phase of GLASO1 Industrialization

2026-04-07 (ET)

08:20:00

Moolec Science Successfully Expresses Bovine Myoglobin in Pea Seeds

2026-02-18 (ET)

09:40:00

Moolec Science SA Trading Halted Due to Volatility Trading Pause

资讯

MLEC 常见问题 —— 由 Alphio AI 解答

Moolec Science SA is a science-based food ingredient company. The Company operates an integrated platform encompassing research & development (R&D), manufacturing, and regulatory capabilities that span from molecular design to validation in both fermenter and field environments. It operates across the United States, Europe, and South America. The Company advances its molecular farming programs in crops such as soy and safflower to produce proteins and lipids with animal-like functionality and plant-based cost structures. It is developing a precision fermentation facility in Finland, under the SynBio Powerlabs brand, which will be dedicated to producing target proteins, enzymes, and other biomolecules using optimized microbial and cellular systems. Its product portfolio includes GLASO, PIGGY SOOY, VALORASOY, and MYCOFOOD. Its GLASO, a safflower-derived oil rich in functional lipids, is being used in formulations for small-animal feed. It operates in the Consumer Non-Cyclicals sector.

Moolec Science SA (MLEC) is not a good buy right now. The current price is $0.85, which is significantly down 79.47% year-to-date and 91.63% over the past year. The RSI is at an extremely low 10.62, indicating the stock is oversold, but this does not guarantee a rebound. The gross margin is negative at -17.81%, reflecting ongoing financial struggles. Additionally, the company's debt to equity ratio is alarmingly high at 789.74%, posing a serious risk to financial stability. While there was a recent surge in stock price due to a reverse stock split and increased shareholder interest, the overall performance and financial health suggest caution. The main risk is the high debt level, which could hinder recovery efforts and investor confidence.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易